EGFR-mutant NSCLC patients can now be tested and monitored to identify the emergence of newly arising EGFR T790M resistance mutations, and be effectively treated with osimertinib, a third generation TKI [14–15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.